CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis
| Principais autores: | , , , , , , , , , , |
|---|---|
| Formato: | Conference item |
| Idioma: | English |
| Publicado em: |
Wiley
2022
|
| Resumo: |
|---|